Alliance Pharma PLC New Agreement for Diclectin in Europe (6255J)
September 13 2016 - 1:01AM
UK Regulatory
TIDMAPH
RNS Number : 6255J
Alliance Pharma PLC
13 September 2016
For immediate release 13 September 2016
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
New Agreement for Diclectin in Key European Countries
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical
company, is pleased to announce that it has signed a further
licensing and distribution agreement with Duchesnay Inc. of Canada
for Diclectin, a proven product to treat nausea and vomiting of
pregnancy. Alliance acquired UK rights to Diclectin in January 2015
and this additional agreement secures rights to launch the product
in a further nine EU countries including Germany, France and Italy
(the "Selected Territories").
This is Alliance's first significant distribution agreement
since acquiring the Sinclair Healthcare Products business in
December 2015, which substantially increased Alliance's European
footprint.
Diclectin has a well-established efficacy and safety profile and
is regarded as the standard of care for nausea and vomiting of
pregnancy in Canada, where it has been used for over 30 years and
has been prescribed for more than 30 million women. In 2013, it was
approved in the United States with an FDA Category A safety rating
for drugs used during pregnancy. Sales continue to grow strongly in
the US, where it is marketed as Diclegis(R).
In the Selected Territories there are approximately 2.5 million
pregnancies each year, and approximately 70% of women will suffer
nausea and vomiting with severe symptoms in 30% of them. It is
estimated that 35% of pregnant women need time off work due to
nausea and vomiting of pregnancy.
Alliance has been progressing Diclectin through the marketing
authorisation process in the UK and anticipates the product's
launch in the second half of 2017. It is expected that regulatory
approvals for the further European territories will follow around a
year later.
Commenting on the agreement, John Dawson, Alliance Pharma's
Chief Executive, said:
"We are delighted to build on our existing partnership with
Duchesnay by acquiring the licensing and distribution rights to
Diclectin in a further nine EU countries. This new agreement
highlights the potential of our strengthened European distribution
base following the acquisition last year of the Sinclair Healthcare
Products business."
Eric Gervais, Duchesnay's Executive Vice-President, added:
"Since we signed the UK rights for Diclectin, our two companies
have collaborated closely and we are very pleased to have agreed
further rights for Diclectin with Alliance. I know both companies
are looking forward to replicating our success in the US and we
look forward to making this product available across Europe as soon
as possible."
For further information:
+ 44 (0) 1249
Alliance Pharma plc 466966
John Dawson, Chief Executive
Andrew Franklin, Chief Financial
Officer
Sarah Robinson, Company
Secretary
www.alliancepharma.co.uk
+ 44 (0) 20 7466
Buchanan 5000
Mark Court / Sophie Cowles
/ Jane Glover
+ 44 (0) 20 7260
Numis Securities Limited 1000
Nominated Adviser: Michael
Meade / Freddie Barnfield
Corporate Broking: James
Black / Toby Adcock
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international specialty
pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has sales in more than 100 countries worldwide via direct
sales, joint ventures and a network of distributors. Alliance has a
strong track record of acquiring the rights to established niche
products and it currently owns or licenses the rights to
approximately 90 pharmaceutical and consumer healthcare products.
The Company continues to explore opportunities to expand its
product portfolio.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRDBGDCGGBBGLD
(END) Dow Jones Newswires
September 13, 2016 02:01 ET (06:01 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024